Global Candida Infections Drugs Market Growth 2026-2032
The global Candida Infections Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Candida infection is a yeast infection where the skin acts as a host organism, and the infection multiplies and grows with the period. Candida albicans are the most common species of this infection. Candida normally lives on the skin and inside the body, such as the throat, gut, mouth, and vagina, without causing problems. It can cause infections if it grows out of control or enters deep into the body.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Candida Infections Drugs Industry Forecast? looks at past sales and reviews total world Candida Infections Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Candida Infections Drugs sales for 2026 through 2032. With Candida Infections Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Candida Infections Drugs industry.
This Insight Report provides a comprehensive analysis of the global Candida Infections Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Candida Infections Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Candida Infections Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Candida Infections Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Candida Infections Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Candida Infections Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Candida infection is a yeast infection where the skin acts as a host organism, and the infection multiplies and grows with the period. Candida albicans are the most common species of this infection. Candida normally lives on the skin and inside the body, such as the throat, gut, mouth, and vagina, without causing problems. It can cause infections if it grows out of control or enters deep into the body.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Candida Infections Drugs Industry Forecast? looks at past sales and reviews total world Candida Infections Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Candida Infections Drugs sales for 2026 through 2032. With Candida Infections Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Candida Infections Drugs industry.
This Insight Report provides a comprehensive analysis of the global Candida Infections Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Candida Infections Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Candida Infections Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Candida Infections Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Candida Infections Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Candida Infections Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Azole
- Nystatin
- Other
- Beriberi
- Jock Itch
- Vaginal Infection
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- F. Hoffmann-La Roche Ltd
- Mylan NV
- Teva Pharmaceutical Industries Ltd
- Sanofi
- Pfizer Inc
- GSK plc
- Novartis AG
- AstraZeneca
- Johnson & Johnson Private Limited
- Sun Pharmaceutical Industries Ltd
- Merck & Co., Inc
- Bristol-Myers Squibb Company
- Lilly
- Amgen Inc
- What is the 10-year outlook for the global Candida Infections Drugs market?
- What factors are driving Candida Infections Drugs market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Candida Infections Drugs market opportunities vary by end market size?
- How does Candida Infections Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Candida Infections Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Candida Infections Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Candida Infections Drugs by Country/Region, 2021, 2025 & 2032
2.2 Candida Infections Drugs Segment by Type
2.2.1 Azole
2.2.2 Nystatin
2.2.3 Other
2.2.4 Candida Infections Drugs Sales by Type
2.2.4.1 Global Candida Infections Drugs Sales Market Share by Type (2021-2026)
2.2.4.2 Global Candida Infections Drugs Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Candida Infections Drugs Sale Price by Type (2021-2026)
2.3 Candida Infections Drugs Segment by Application
2.3.1 Beriberi
2.3.2 Jock Itch
2.3.3 Vaginal Infection
2.3.4 Other
2.3.5 Candida Infections Drugs Sales by Application
2.3.5.1 Global Candida Infections Drugs Sale Market Share by Application (2021-2026)
2.3.5.2 Global Candida Infections Drugs Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Candida Infections Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Candida Infections Drugs Breakdown Data by Company
3.1.1 Global Candida Infections Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Candida Infections Drugs Sales Market Share by Company (2021-2026)
3.2 Global Candida Infections Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Candida Infections Drugs Revenue by Company (2021-2026)
3.2.2 Global Candida Infections Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Candida Infections Drugs Sale Price by Company
3.4 Key Manufacturers Candida Infections Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Candida Infections Drugs Product Location Distribution
3.4.2 Players Candida Infections Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR CANDIDA INFECTIONS DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Candida Infections Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Candida Infections Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Candida Infections Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Candida Infections Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Candida Infections Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Candida Infections Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Candida Infections Drugs Sales Growth
4.4 APAC Candida Infections Drugs Sales Growth
4.5 Europe Candida Infections Drugs Sales Growth
4.6 Middle East & Africa Candida Infections Drugs Sales Growth
5 AMERICAS
5.1 Americas Candida Infections Drugs Sales by Country
5.1.1 Americas Candida Infections Drugs Sales by Country (2021-2026)
5.1.2 Americas Candida Infections Drugs Revenue by Country (2021-2026)
5.2 Americas Candida Infections Drugs Sales by Type (2021-2026)
5.3 Americas Candida Infections Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Candida Infections Drugs Sales by Region
6.1.1 APAC Candida Infections Drugs Sales by Region (2021-2026)
6.1.2 APAC Candida Infections Drugs Revenue by Region (2021-2026)
6.2 APAC Candida Infections Drugs Sales by Type (2021-2026)
6.3 APAC Candida Infections Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Candida Infections Drugs by Country
7.1.1 Europe Candida Infections Drugs Sales by Country (2021-2026)
7.1.2 Europe Candida Infections Drugs Revenue by Country (2021-2026)
7.2 Europe Candida Infections Drugs Sales by Type (2021-2026)
7.3 Europe Candida Infections Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Candida Infections Drugs by Country
8.1.1 Middle East & Africa Candida Infections Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Candida Infections Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Candida Infections Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Candida Infections Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Candida Infections Drugs
10.3 Manufacturing Process Analysis of Candida Infections Drugs
10.4 Industry Chain Structure of Candida Infections Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Candida Infections Drugs Distributors
11.3 Candida Infections Drugs Customer
12 WORLD FORECAST REVIEW FOR CANDIDA INFECTIONS DRUGS BY GEOGRAPHIC REGION
12.1 Global Candida Infections Drugs Market Size Forecast by Region
12.1.1 Global Candida Infections Drugs Forecast by Region (2027-2032)
12.1.2 Global Candida Infections Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Candida Infections Drugs Forecast by Type (2027-2032)
12.7 Global Candida Infections Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 F. Hoffmann-La Roche Ltd
13.1.1 F. Hoffmann-La Roche Ltd Company Information
13.1.2 F. Hoffmann-La Roche Ltd Candida Infections Drugs Product Portfolios and Specifications
13.1.3 F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.1.5 F. Hoffmann-La Roche Ltd Latest Developments
13.2 Mylan NV
13.2.1 Mylan NV Company Information
13.2.2 Mylan NV Candida Infections Drugs Product Portfolios and Specifications
13.2.3 Mylan NV Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Mylan NV Main Business Overview
13.2.5 Mylan NV Latest Developments
13.3 Teva Pharmaceutical Industries Ltd
13.3.1 Teva Pharmaceutical Industries Ltd Company Information
13.3.2 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolios and Specifications
13.3.3 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.3.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Candida Infections Drugs Product Portfolios and Specifications
13.4.3 Sanofi Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Pfizer Inc
13.5.1 Pfizer Inc Company Information
13.5.2 Pfizer Inc Candida Infections Drugs Product Portfolios and Specifications
13.5.3 Pfizer Inc Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Pfizer Inc Main Business Overview
13.5.5 Pfizer Inc Latest Developments
13.6 GSK plc
13.6.1 GSK plc Company Information
13.6.2 GSK plc Candida Infections Drugs Product Portfolios and Specifications
13.6.3 GSK plc Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 GSK plc Main Business Overview
13.6.5 GSK plc Latest Developments
13.7 Novartis AG
13.7.1 Novartis AG Company Information
13.7.2 Novartis AG Candida Infections Drugs Product Portfolios and Specifications
13.7.3 Novartis AG Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Novartis AG Main Business Overview
13.7.5 Novartis AG Latest Developments
13.8 AstraZeneca
13.8.1 AstraZeneca Company Information
13.8.2 AstraZeneca Candida Infections Drugs Product Portfolios and Specifications
13.8.3 AstraZeneca Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 AstraZeneca Main Business Overview
13.8.5 AstraZeneca Latest Developments
13.9 Johnson & Johnson Private Limited
13.9.1 Johnson & Johnson Private Limited Company Information
13.9.2 Johnson & Johnson Private Limited Candida Infections Drugs Product Portfolios and Specifications
13.9.3 Johnson & Johnson Private Limited Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Johnson & Johnson Private Limited Main Business Overview
13.9.5 Johnson & Johnson Private Limited Latest Developments
13.10 Sun Pharmaceutical Industries Ltd
13.10.1 Sun Pharmaceutical Industries Ltd Company Information
13.10.2 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolios and Specifications
13.10.3 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.10.5 Sun Pharmaceutical Industries Ltd Latest Developments
13.11 Merck & Co., Inc
13.11.1 Merck & Co., Inc Company Information
13.11.2 Merck & Co., Inc Candida Infections Drugs Product Portfolios and Specifications
13.11.3 Merck & Co., Inc Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Merck & Co., Inc Main Business Overview
13.11.5 Merck & Co., Inc Latest Developments
13.12 Bristol-Myers Squibb Company
13.12.1 Bristol-Myers Squibb Company Company Information
13.12.2 Bristol-Myers Squibb Company Candida Infections Drugs Product Portfolios and Specifications
13.12.3 Bristol-Myers Squibb Company Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Bristol-Myers Squibb Company Main Business Overview
13.12.5 Bristol-Myers Squibb Company Latest Developments
13.13 Lilly
13.13.1 Lilly Company Information
13.13.2 Lilly Candida Infections Drugs Product Portfolios and Specifications
13.13.3 Lilly Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Lilly Main Business Overview
13.13.5 Lilly Latest Developments
13.14 Amgen Inc
13.14.1 Amgen Inc Company Information
13.14.2 Amgen Inc Candida Infections Drugs Product Portfolios and Specifications
13.14.3 Amgen Inc Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Amgen Inc Main Business Overview
13.14.5 Amgen Inc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Candida Infections Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Candida Infections Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Candida Infections Drugs by Country/Region, 2021, 2025 & 2032
2.2 Candida Infections Drugs Segment by Type
2.2.1 Azole
2.2.2 Nystatin
2.2.3 Other
2.2.4 Candida Infections Drugs Sales by Type
2.2.4.1 Global Candida Infections Drugs Sales Market Share by Type (2021-2026)
2.2.4.2 Global Candida Infections Drugs Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Candida Infections Drugs Sale Price by Type (2021-2026)
2.3 Candida Infections Drugs Segment by Application
2.3.1 Beriberi
2.3.2 Jock Itch
2.3.3 Vaginal Infection
2.3.4 Other
2.3.5 Candida Infections Drugs Sales by Application
2.3.5.1 Global Candida Infections Drugs Sale Market Share by Application (2021-2026)
2.3.5.2 Global Candida Infections Drugs Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Candida Infections Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Candida Infections Drugs Breakdown Data by Company
3.1.1 Global Candida Infections Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Candida Infections Drugs Sales Market Share by Company (2021-2026)
3.2 Global Candida Infections Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Candida Infections Drugs Revenue by Company (2021-2026)
3.2.2 Global Candida Infections Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Candida Infections Drugs Sale Price by Company
3.4 Key Manufacturers Candida Infections Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Candida Infections Drugs Product Location Distribution
3.4.2 Players Candida Infections Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR CANDIDA INFECTIONS DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Candida Infections Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Candida Infections Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Candida Infections Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Candida Infections Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Candida Infections Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Candida Infections Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Candida Infections Drugs Sales Growth
4.4 APAC Candida Infections Drugs Sales Growth
4.5 Europe Candida Infections Drugs Sales Growth
4.6 Middle East & Africa Candida Infections Drugs Sales Growth
5 AMERICAS
5.1 Americas Candida Infections Drugs Sales by Country
5.1.1 Americas Candida Infections Drugs Sales by Country (2021-2026)
5.1.2 Americas Candida Infections Drugs Revenue by Country (2021-2026)
5.2 Americas Candida Infections Drugs Sales by Type (2021-2026)
5.3 Americas Candida Infections Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Candida Infections Drugs Sales by Region
6.1.1 APAC Candida Infections Drugs Sales by Region (2021-2026)
6.1.2 APAC Candida Infections Drugs Revenue by Region (2021-2026)
6.2 APAC Candida Infections Drugs Sales by Type (2021-2026)
6.3 APAC Candida Infections Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Candida Infections Drugs by Country
7.1.1 Europe Candida Infections Drugs Sales by Country (2021-2026)
7.1.2 Europe Candida Infections Drugs Revenue by Country (2021-2026)
7.2 Europe Candida Infections Drugs Sales by Type (2021-2026)
7.3 Europe Candida Infections Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Candida Infections Drugs by Country
8.1.1 Middle East & Africa Candida Infections Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Candida Infections Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Candida Infections Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Candida Infections Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Candida Infections Drugs
10.3 Manufacturing Process Analysis of Candida Infections Drugs
10.4 Industry Chain Structure of Candida Infections Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Candida Infections Drugs Distributors
11.3 Candida Infections Drugs Customer
12 WORLD FORECAST REVIEW FOR CANDIDA INFECTIONS DRUGS BY GEOGRAPHIC REGION
12.1 Global Candida Infections Drugs Market Size Forecast by Region
12.1.1 Global Candida Infections Drugs Forecast by Region (2027-2032)
12.1.2 Global Candida Infections Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Candida Infections Drugs Forecast by Type (2027-2032)
12.7 Global Candida Infections Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 F. Hoffmann-La Roche Ltd
13.1.1 F. Hoffmann-La Roche Ltd Company Information
13.1.2 F. Hoffmann-La Roche Ltd Candida Infections Drugs Product Portfolios and Specifications
13.1.3 F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.1.5 F. Hoffmann-La Roche Ltd Latest Developments
13.2 Mylan NV
13.2.1 Mylan NV Company Information
13.2.2 Mylan NV Candida Infections Drugs Product Portfolios and Specifications
13.2.3 Mylan NV Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Mylan NV Main Business Overview
13.2.5 Mylan NV Latest Developments
13.3 Teva Pharmaceutical Industries Ltd
13.3.1 Teva Pharmaceutical Industries Ltd Company Information
13.3.2 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolios and Specifications
13.3.3 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.3.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Candida Infections Drugs Product Portfolios and Specifications
13.4.3 Sanofi Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Pfizer Inc
13.5.1 Pfizer Inc Company Information
13.5.2 Pfizer Inc Candida Infections Drugs Product Portfolios and Specifications
13.5.3 Pfizer Inc Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Pfizer Inc Main Business Overview
13.5.5 Pfizer Inc Latest Developments
13.6 GSK plc
13.6.1 GSK plc Company Information
13.6.2 GSK plc Candida Infections Drugs Product Portfolios and Specifications
13.6.3 GSK plc Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 GSK plc Main Business Overview
13.6.5 GSK plc Latest Developments
13.7 Novartis AG
13.7.1 Novartis AG Company Information
13.7.2 Novartis AG Candida Infections Drugs Product Portfolios and Specifications
13.7.3 Novartis AG Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Novartis AG Main Business Overview
13.7.5 Novartis AG Latest Developments
13.8 AstraZeneca
13.8.1 AstraZeneca Company Information
13.8.2 AstraZeneca Candida Infections Drugs Product Portfolios and Specifications
13.8.3 AstraZeneca Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 AstraZeneca Main Business Overview
13.8.5 AstraZeneca Latest Developments
13.9 Johnson & Johnson Private Limited
13.9.1 Johnson & Johnson Private Limited Company Information
13.9.2 Johnson & Johnson Private Limited Candida Infections Drugs Product Portfolios and Specifications
13.9.3 Johnson & Johnson Private Limited Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Johnson & Johnson Private Limited Main Business Overview
13.9.5 Johnson & Johnson Private Limited Latest Developments
13.10 Sun Pharmaceutical Industries Ltd
13.10.1 Sun Pharmaceutical Industries Ltd Company Information
13.10.2 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolios and Specifications
13.10.3 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.10.5 Sun Pharmaceutical Industries Ltd Latest Developments
13.11 Merck & Co., Inc
13.11.1 Merck & Co., Inc Company Information
13.11.2 Merck & Co., Inc Candida Infections Drugs Product Portfolios and Specifications
13.11.3 Merck & Co., Inc Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Merck & Co., Inc Main Business Overview
13.11.5 Merck & Co., Inc Latest Developments
13.12 Bristol-Myers Squibb Company
13.12.1 Bristol-Myers Squibb Company Company Information
13.12.2 Bristol-Myers Squibb Company Candida Infections Drugs Product Portfolios and Specifications
13.12.3 Bristol-Myers Squibb Company Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Bristol-Myers Squibb Company Main Business Overview
13.12.5 Bristol-Myers Squibb Company Latest Developments
13.13 Lilly
13.13.1 Lilly Company Information
13.13.2 Lilly Candida Infections Drugs Product Portfolios and Specifications
13.13.3 Lilly Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Lilly Main Business Overview
13.13.5 Lilly Latest Developments
13.14 Amgen Inc
13.14.1 Amgen Inc Company Information
13.14.2 Amgen Inc Candida Infections Drugs Product Portfolios and Specifications
13.14.3 Amgen Inc Candida Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Amgen Inc Main Business Overview
13.14.5 Amgen Inc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Candida Infections Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Candida Infections Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Azole
Table 4. Major Players of Nystatin
Table 5. Major Players of Other
Table 6. Global Candida Infections Drugs Sales by Type (2021-2026) & (K Units)
Table 7. Global Candida Infections Drugs Sales Market Share by Type (2021-2026)
Table 8. Global Candida Infections Drugs Revenue by Type (2021-2026) & ($ million)
Table 9. Global Candida Infections Drugs Revenue Market Share by Type (2021-2026)
Table 10. Global Candida Infections Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Candida Infections Drugs Sale by Application (2021-2026) & (K Units)
Table 12. Global Candida Infections Drugs Sale Market Share by Application (2021-2026)
Table 13. Global Candida Infections Drugs Revenue by Application (2021-2026) & ($ million)
Table 14. Global Candida Infections Drugs Revenue Market Share by Application (2021-2026)
Table 15. Global Candida Infections Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Candida Infections Drugs Sales by Company (2021-2026) & (K Units)
Table 17. Global Candida Infections Drugs Sales Market Share by Company (2021-2026)
Table 18. Global Candida Infections Drugs Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Candida Infections Drugs Revenue Market Share by Company (2021-2026)
Table 20. Global Candida Infections Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Candida Infections Drugs Producing Area Distribution and Sales Area
Table 22. Players Candida Infections Drugs Products Offered
Table 23. Candida Infections Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Candida Infections Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Candida Infections Drugs Sales Market Share Geographic Region (2021-2026)
Table 28. Global Candida Infections Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Candida Infections Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Candida Infections Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Candida Infections Drugs Sales Market Share by Country/Region (2021-2026)
Table 32. Global Candida Infections Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Candida Infections Drugs Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Candida Infections Drugs Sales by Country (2021-2026) & (K Units)
Table 35. Americas Candida Infections Drugs Sales Market Share by Country (2021-2026)
Table 36. Americas Candida Infections Drugs Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Candida Infections Drugs Sales by Type (2021-2026) & (K Units)
Table 38. Americas Candida Infections Drugs Sales by Application (2021-2026) & (K Units)
Table 39. APAC Candida Infections Drugs Sales by Region (2021-2026) & (K Units)
Table 40. APAC Candida Infections Drugs Sales Market Share by Region (2021-2026)
Table 41. APAC Candida Infections Drugs Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Candida Infections Drugs Sales by Type (2021-2026) & (K Units)
Table 43. APAC Candida Infections Drugs Sales by Application (2021-2026) & (K Units)
Table 44. Europe Candida Infections Drugs Sales by Country (2021-2026) & (K Units)
Table 45. Europe Candida Infections Drugs Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Candida Infections Drugs Sales by Type (2021-2026) & (K Units)
Table 47. Europe Candida Infections Drugs Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Candida Infections Drugs Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Candida Infections Drugs Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Candida Infections Drugs Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Candida Infections Drugs Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Candida Infections Drugs
Table 53. Key Market Challenges & Risks of Candida Infections Drugs
Table 54. Key Industry Trends of Candida Infections Drugs
Table 55. Candida Infections Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Candida Infections Drugs Distributors List
Table 58. Candida Infections Drugs Customer List
Table 59. Global Candida Infections Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Candida Infections Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Candida Infections Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Candida Infections Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Candida Infections Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Candida Infections Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Candida Infections Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Candida Infections Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Candida Infections Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Candida Infections Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Candida Infections Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Candida Infections Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Candida Infections Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Candida Infections Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. F. Hoffmann-La Roche Ltd Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. F. Hoffmann-La Roche Ltd Candida Infections Drugs Product Portfolios and Specifications
Table 75. F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. F. Hoffmann-La Roche Ltd Main Business
Table 77. F. Hoffmann-La Roche Ltd Latest Developments
Table 78. Mylan NV Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Mylan NV Candida Infections Drugs Product Portfolios and Specifications
Table 80. Mylan NV Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Mylan NV Main Business
Table 82. Mylan NV Latest Developments
Table 83. Teva Pharmaceutical Industries Ltd Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolios and Specifications
Table 85. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Teva Pharmaceutical Industries Ltd Main Business
Table 87. Teva Pharmaceutical Industries Ltd Latest Developments
Table 88. Sanofi Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Candida Infections Drugs Product Portfolios and Specifications
Table 90. Sanofi Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Sanofi Main Business
Table 92. Sanofi Latest Developments
Table 93. Pfizer Inc Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Inc Candida Infections Drugs Product Portfolios and Specifications
Table 95. Pfizer Inc Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Pfizer Inc Main Business
Table 97. Pfizer Inc Latest Developments
Table 98. GSK plc Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. GSK plc Candida Infections Drugs Product Portfolios and Specifications
Table 100. GSK plc Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. GSK plc Main Business
Table 102. GSK plc Latest Developments
Table 103. Novartis AG Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Novartis AG Candida Infections Drugs Product Portfolios and Specifications
Table 105. Novartis AG Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Novartis AG Main Business
Table 107. Novartis AG Latest Developments
Table 108. AstraZeneca Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. AstraZeneca Candida Infections Drugs Product Portfolios and Specifications
Table 110. AstraZeneca Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. AstraZeneca Main Business
Table 112. AstraZeneca Latest Developments
Table 113. Johnson & Johnson Private Limited Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Johnson & Johnson Private Limited Candida Infections Drugs Product Portfolios and Specifications
Table 115. Johnson & Johnson Private Limited Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Johnson & Johnson Private Limited Main Business
Table 117. Johnson & Johnson Private Limited Latest Developments
Table 118. Sun Pharmaceutical Industries Ltd Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolios and Specifications
Table 120. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Sun Pharmaceutical Industries Ltd Main Business
Table 122. Sun Pharmaceutical Industries Ltd Latest Developments
Table 123. Merck & Co., Inc Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Merck & Co., Inc Candida Infections Drugs Product Portfolios and Specifications
Table 125. Merck & Co., Inc Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Merck & Co., Inc Main Business
Table 127. Merck & Co., Inc Latest Developments
Table 128. Bristol-Myers Squibb Company Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Bristol-Myers Squibb Company Candida Infections Drugs Product Portfolios and Specifications
Table 130. Bristol-Myers Squibb Company Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Bristol-Myers Squibb Company Main Business
Table 132. Bristol-Myers Squibb Company Latest Developments
Table 133. Lilly Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Lilly Candida Infections Drugs Product Portfolios and Specifications
Table 135. Lilly Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Lilly Main Business
Table 137. Lilly Latest Developments
Table 138. Amgen Inc Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Amgen Inc Candida Infections Drugs Product Portfolios and Specifications
Table 140. Amgen Inc Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Amgen Inc Main Business
Table 142. Amgen Inc Latest Developments
Table 1. Candida Infections Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Candida Infections Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Azole
Table 4. Major Players of Nystatin
Table 5. Major Players of Other
Table 6. Global Candida Infections Drugs Sales by Type (2021-2026) & (K Units)
Table 7. Global Candida Infections Drugs Sales Market Share by Type (2021-2026)
Table 8. Global Candida Infections Drugs Revenue by Type (2021-2026) & ($ million)
Table 9. Global Candida Infections Drugs Revenue Market Share by Type (2021-2026)
Table 10. Global Candida Infections Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Candida Infections Drugs Sale by Application (2021-2026) & (K Units)
Table 12. Global Candida Infections Drugs Sale Market Share by Application (2021-2026)
Table 13. Global Candida Infections Drugs Revenue by Application (2021-2026) & ($ million)
Table 14. Global Candida Infections Drugs Revenue Market Share by Application (2021-2026)
Table 15. Global Candida Infections Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Candida Infections Drugs Sales by Company (2021-2026) & (K Units)
Table 17. Global Candida Infections Drugs Sales Market Share by Company (2021-2026)
Table 18. Global Candida Infections Drugs Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Candida Infections Drugs Revenue Market Share by Company (2021-2026)
Table 20. Global Candida Infections Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Candida Infections Drugs Producing Area Distribution and Sales Area
Table 22. Players Candida Infections Drugs Products Offered
Table 23. Candida Infections Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Candida Infections Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Candida Infections Drugs Sales Market Share Geographic Region (2021-2026)
Table 28. Global Candida Infections Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Candida Infections Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Candida Infections Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Candida Infections Drugs Sales Market Share by Country/Region (2021-2026)
Table 32. Global Candida Infections Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Candida Infections Drugs Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Candida Infections Drugs Sales by Country (2021-2026) & (K Units)
Table 35. Americas Candida Infections Drugs Sales Market Share by Country (2021-2026)
Table 36. Americas Candida Infections Drugs Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Candida Infections Drugs Sales by Type (2021-2026) & (K Units)
Table 38. Americas Candida Infections Drugs Sales by Application (2021-2026) & (K Units)
Table 39. APAC Candida Infections Drugs Sales by Region (2021-2026) & (K Units)
Table 40. APAC Candida Infections Drugs Sales Market Share by Region (2021-2026)
Table 41. APAC Candida Infections Drugs Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Candida Infections Drugs Sales by Type (2021-2026) & (K Units)
Table 43. APAC Candida Infections Drugs Sales by Application (2021-2026) & (K Units)
Table 44. Europe Candida Infections Drugs Sales by Country (2021-2026) & (K Units)
Table 45. Europe Candida Infections Drugs Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Candida Infections Drugs Sales by Type (2021-2026) & (K Units)
Table 47. Europe Candida Infections Drugs Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Candida Infections Drugs Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Candida Infections Drugs Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Candida Infections Drugs Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Candida Infections Drugs Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Candida Infections Drugs
Table 53. Key Market Challenges & Risks of Candida Infections Drugs
Table 54. Key Industry Trends of Candida Infections Drugs
Table 55. Candida Infections Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Candida Infections Drugs Distributors List
Table 58. Candida Infections Drugs Customer List
Table 59. Global Candida Infections Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Candida Infections Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Candida Infections Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Candida Infections Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Candida Infections Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Candida Infections Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Candida Infections Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Candida Infections Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Candida Infections Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Candida Infections Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Candida Infections Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Candida Infections Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Candida Infections Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Candida Infections Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. F. Hoffmann-La Roche Ltd Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. F. Hoffmann-La Roche Ltd Candida Infections Drugs Product Portfolios and Specifications
Table 75. F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. F. Hoffmann-La Roche Ltd Main Business
Table 77. F. Hoffmann-La Roche Ltd Latest Developments
Table 78. Mylan NV Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Mylan NV Candida Infections Drugs Product Portfolios and Specifications
Table 80. Mylan NV Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Mylan NV Main Business
Table 82. Mylan NV Latest Developments
Table 83. Teva Pharmaceutical Industries Ltd Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolios and Specifications
Table 85. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Teva Pharmaceutical Industries Ltd Main Business
Table 87. Teva Pharmaceutical Industries Ltd Latest Developments
Table 88. Sanofi Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Candida Infections Drugs Product Portfolios and Specifications
Table 90. Sanofi Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Sanofi Main Business
Table 92. Sanofi Latest Developments
Table 93. Pfizer Inc Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Inc Candida Infections Drugs Product Portfolios and Specifications
Table 95. Pfizer Inc Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Pfizer Inc Main Business
Table 97. Pfizer Inc Latest Developments
Table 98. GSK plc Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. GSK plc Candida Infections Drugs Product Portfolios and Specifications
Table 100. GSK plc Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. GSK plc Main Business
Table 102. GSK plc Latest Developments
Table 103. Novartis AG Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Novartis AG Candida Infections Drugs Product Portfolios and Specifications
Table 105. Novartis AG Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Novartis AG Main Business
Table 107. Novartis AG Latest Developments
Table 108. AstraZeneca Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. AstraZeneca Candida Infections Drugs Product Portfolios and Specifications
Table 110. AstraZeneca Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. AstraZeneca Main Business
Table 112. AstraZeneca Latest Developments
Table 113. Johnson & Johnson Private Limited Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Johnson & Johnson Private Limited Candida Infections Drugs Product Portfolios and Specifications
Table 115. Johnson & Johnson Private Limited Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Johnson & Johnson Private Limited Main Business
Table 117. Johnson & Johnson Private Limited Latest Developments
Table 118. Sun Pharmaceutical Industries Ltd Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolios and Specifications
Table 120. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Sun Pharmaceutical Industries Ltd Main Business
Table 122. Sun Pharmaceutical Industries Ltd Latest Developments
Table 123. Merck & Co., Inc Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Merck & Co., Inc Candida Infections Drugs Product Portfolios and Specifications
Table 125. Merck & Co., Inc Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Merck & Co., Inc Main Business
Table 127. Merck & Co., Inc Latest Developments
Table 128. Bristol-Myers Squibb Company Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Bristol-Myers Squibb Company Candida Infections Drugs Product Portfolios and Specifications
Table 130. Bristol-Myers Squibb Company Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Bristol-Myers Squibb Company Main Business
Table 132. Bristol-Myers Squibb Company Latest Developments
Table 133. Lilly Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Lilly Candida Infections Drugs Product Portfolios and Specifications
Table 135. Lilly Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Lilly Main Business
Table 137. Lilly Latest Developments
Table 138. Amgen Inc Basic Information, Candida Infections Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Amgen Inc Candida Infections Drugs Product Portfolios and Specifications
Table 140. Amgen Inc Candida Infections Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. Amgen Inc Main Business
Table 142. Amgen Inc Latest Developments
LIST OF FIGURES
Figure 1. Picture of Candida Infections Drugs
Figure 2. Candida Infections Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Candida Infections Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Candida Infections Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Candida Infections Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Candida Infections Drugs Sales Market Share by Country/Region (2025)
Figure 10. Candida Infections Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Azole
Figure 12. Product Picture of Nystatin
Figure 13. Product Picture of Other
Figure 14. Global Candida Infections Drugs Sales Market Share by Type in 2026
Figure 15. Global Candida Infections Drugs Revenue Market Share by Type (2021-2026)
Figure 16. Candida Infections Drugs Consumed in Beriberi
Figure 17. Global Candida Infections Drugs Market: Beriberi (2021-2026) & (K Units)
Figure 18. Candida Infections Drugs Consumed in Jock Itch
Figure 19. Global Candida Infections Drugs Market: Jock Itch (2021-2026) & (K Units)
Figure 20. Candida Infections Drugs Consumed in Vaginal Infection
Figure 21. Global Candida Infections Drugs Market: Vaginal Infection (2021-2026) & (K Units)
Figure 22. Candida Infections Drugs Consumed in Other
Figure 23. Global Candida Infections Drugs Market: Other (2021-2026) & (K Units)
Figure 24. Global Candida Infections Drugs Sale Market Share by Application (2025)
Figure 25. Global Candida Infections Drugs Revenue Market Share by Application in 2026
Figure 26. Candida Infections Drugs Sales by Company in 2026 (K Units)
Figure 27. Global Candida Infections Drugs Sales Market Share by Company in 2026
Figure 28. Candida Infections Drugs Revenue by Company in 2026 ($ millions)
Figure 29. Global Candida Infections Drugs Revenue Market Share by Company in 2026
Figure 30. Global Candida Infections Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 31. Global Candida Infections Drugs Revenue Market Share by Geographic Region in 2026
Figure 32. Americas Candida Infections Drugs Sales 2021-2026 (K Units)
Figure 33. Americas Candida Infections Drugs Revenue 2021-2026 ($ millions)
Figure 34. APAC Candida Infections Drugs Sales 2021-2026 (K Units)
Figure 35. APAC Candida Infections Drugs Revenue 2021-2026 ($ millions)
Figure 36. Europe Candida Infections Drugs Sales 2021-2026 (K Units)
Figure 37. Europe Candida Infections Drugs Revenue 2021-2026 ($ millions)
Figure 38. Middle East & Africa Candida Infections Drugs Sales 2021-2026 (K Units)
Figure 39. Middle East & Africa Candida Infections Drugs Revenue 2021-2026 ($ millions)
Figure 40. Americas Candida Infections Drugs Sales Market Share by Country in 2026
Figure 41. Americas Candida Infections Drugs Revenue Market Share by Country (2021-2026)
Figure 42. Americas Candida Infections Drugs Sales Market Share by Type (2021-2026)
Figure 43. Americas Candida Infections Drugs Sales Market Share by Application (2021-2026)
Figure 44. United States Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 45. Canada Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 46. Mexico Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 47. Brazil Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 48. APAC Candida Infections Drugs Sales Market Share by Region in 2026
Figure 49. APAC Candida Infections Drugs Revenue Market Share by Region (2021-2026)
Figure 50. APAC Candida Infections Drugs Sales Market Share by Type (2021-2026)
Figure 51. APAC Candida Infections Drugs Sales Market Share by Application (2021-2026)
Figure 52. China Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. Japan Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. South Korea Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 55. Southeast Asia Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 56. India Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 57. Australia Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 58. China Taiwan Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 59. Europe Candida Infections Drugs Sales Market Share by Country in 2026
Figure 60. Europe Candida Infections Drugs Revenue Market Share by Country (2021-2026)
Figure 61. Europe Candida Infections Drugs Sales Market Share by Type (2021-2026)
Figure 62. Europe Candida Infections Drugs Sales Market Share by Application (2021-2026)
Figure 63. Germany Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. France Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. UK Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Italy Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. Russia Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 68. Middle East & Africa Candida Infections Drugs Sales Market Share by Country (2021-2026)
Figure 69. Middle East & Africa Candida Infections Drugs Sales Market Share by Type (2021-2026)
Figure 70. Middle East & Africa Candida Infections Drugs Sales Market Share by Application (2021-2026)
Figure 71. Egypt Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. South Africa Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Israel Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. Turkey Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 75. GCC Countries Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Candida Infections Drugs in 2026
Figure 77. Manufacturing Process Analysis of Candida Infections Drugs
Figure 78. Industry Chain Structure of Candida Infections Drugs
Figure 79. Channels of Distribution
Figure 80. Global Candida Infections Drugs Sales Market Forecast by Region (2027-2032)
Figure 81. Global Candida Infections Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 82. Global Candida Infections Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 83. Global Candida Infections Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 84. Global Candida Infections Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 85. Global Candida Infections Drugs Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Candida Infections Drugs
Figure 2. Candida Infections Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Candida Infections Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Candida Infections Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Candida Infections Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Candida Infections Drugs Sales Market Share by Country/Region (2025)
Figure 10. Candida Infections Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Azole
Figure 12. Product Picture of Nystatin
Figure 13. Product Picture of Other
Figure 14. Global Candida Infections Drugs Sales Market Share by Type in 2026
Figure 15. Global Candida Infections Drugs Revenue Market Share by Type (2021-2026)
Figure 16. Candida Infections Drugs Consumed in Beriberi
Figure 17. Global Candida Infections Drugs Market: Beriberi (2021-2026) & (K Units)
Figure 18. Candida Infections Drugs Consumed in Jock Itch
Figure 19. Global Candida Infections Drugs Market: Jock Itch (2021-2026) & (K Units)
Figure 20. Candida Infections Drugs Consumed in Vaginal Infection
Figure 21. Global Candida Infections Drugs Market: Vaginal Infection (2021-2026) & (K Units)
Figure 22. Candida Infections Drugs Consumed in Other
Figure 23. Global Candida Infections Drugs Market: Other (2021-2026) & (K Units)
Figure 24. Global Candida Infections Drugs Sale Market Share by Application (2025)
Figure 25. Global Candida Infections Drugs Revenue Market Share by Application in 2026
Figure 26. Candida Infections Drugs Sales by Company in 2026 (K Units)
Figure 27. Global Candida Infections Drugs Sales Market Share by Company in 2026
Figure 28. Candida Infections Drugs Revenue by Company in 2026 ($ millions)
Figure 29. Global Candida Infections Drugs Revenue Market Share by Company in 2026
Figure 30. Global Candida Infections Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 31. Global Candida Infections Drugs Revenue Market Share by Geographic Region in 2026
Figure 32. Americas Candida Infections Drugs Sales 2021-2026 (K Units)
Figure 33. Americas Candida Infections Drugs Revenue 2021-2026 ($ millions)
Figure 34. APAC Candida Infections Drugs Sales 2021-2026 (K Units)
Figure 35. APAC Candida Infections Drugs Revenue 2021-2026 ($ millions)
Figure 36. Europe Candida Infections Drugs Sales 2021-2026 (K Units)
Figure 37. Europe Candida Infections Drugs Revenue 2021-2026 ($ millions)
Figure 38. Middle East & Africa Candida Infections Drugs Sales 2021-2026 (K Units)
Figure 39. Middle East & Africa Candida Infections Drugs Revenue 2021-2026 ($ millions)
Figure 40. Americas Candida Infections Drugs Sales Market Share by Country in 2026
Figure 41. Americas Candida Infections Drugs Revenue Market Share by Country (2021-2026)
Figure 42. Americas Candida Infections Drugs Sales Market Share by Type (2021-2026)
Figure 43. Americas Candida Infections Drugs Sales Market Share by Application (2021-2026)
Figure 44. United States Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 45. Canada Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 46. Mexico Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 47. Brazil Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 48. APAC Candida Infections Drugs Sales Market Share by Region in 2026
Figure 49. APAC Candida Infections Drugs Revenue Market Share by Region (2021-2026)
Figure 50. APAC Candida Infections Drugs Sales Market Share by Type (2021-2026)
Figure 51. APAC Candida Infections Drugs Sales Market Share by Application (2021-2026)
Figure 52. China Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. Japan Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. South Korea Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 55. Southeast Asia Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 56. India Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 57. Australia Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 58. China Taiwan Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 59. Europe Candida Infections Drugs Sales Market Share by Country in 2026
Figure 60. Europe Candida Infections Drugs Revenue Market Share by Country (2021-2026)
Figure 61. Europe Candida Infections Drugs Sales Market Share by Type (2021-2026)
Figure 62. Europe Candida Infections Drugs Sales Market Share by Application (2021-2026)
Figure 63. Germany Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. France Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. UK Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Italy Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. Russia Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 68. Middle East & Africa Candida Infections Drugs Sales Market Share by Country (2021-2026)
Figure 69. Middle East & Africa Candida Infections Drugs Sales Market Share by Type (2021-2026)
Figure 70. Middle East & Africa Candida Infections Drugs Sales Market Share by Application (2021-2026)
Figure 71. Egypt Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. South Africa Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Israel Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. Turkey Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 75. GCC Countries Candida Infections Drugs Revenue Growth 2021-2026 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Candida Infections Drugs in 2026
Figure 77. Manufacturing Process Analysis of Candida Infections Drugs
Figure 78. Industry Chain Structure of Candida Infections Drugs
Figure 79. Channels of Distribution
Figure 80. Global Candida Infections Drugs Sales Market Forecast by Region (2027-2032)
Figure 81. Global Candida Infections Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 82. Global Candida Infections Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 83. Global Candida Infections Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 84. Global Candida Infections Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 85. Global Candida Infections Drugs Revenue Market Share Forecast by Application (2027-2032)
